Check 35,000+ stocks against 26 valuation models and 37 quality factors

PT Kalbe Farma Tbk. (PTKFF) fair value: what the stock is really worth

We calculate from audited financials what PT Kalbe Farma Tbk. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN ID1000125107

Thin data Sep 13, 2026

PT Kalbe Farma Tbk.

PTKFF · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $0.0931 · Strongly undervalued (+78%)

✓Quality 74/100

✓Healthy Growth (revenue 5y +8.9 %/yr)

!Thin margins · 10.0% net margin (TTM)

✓Low debt · generates free cash flow

!Moderate moat 57/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.0669 to bull $0.1140 Growth analysisrevenue history, year by year Quality 74/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch PT Kalbe Farma Tbk., for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range $0.0099 – $0.1451 · fair‑value band $0.0669 – $0.1140 · the $0.0524 price screens below the $0.0931 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Stock analysis

PT Kalbe Farma Tbk., (PTKFF) currently trades at $0.0524, while our model-based Fair Value estimate is $0.0931, implying the stock looks roughly 43.7% undervalued today.

Valuation

Bull case: the Multiples group reads highest at a median of $0.1002 per share, and 20 of the 24 models we run sit above the $0.0524 price.

Bear case: the Asset-Based group reads lowest at $0.0247, and 4 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0669 (bear) to $0.1140 (bull), the price of $0.0524 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

PT Kalbe Farma Tbk., reported revenue of 35.3T IDR in FY2025 versus 26.3T IDR in FY2021, a compound +7.7%/yr. Reported net income was 3.7T IDR in FY2025, compounding +3.6%/yr from FY2021.

Key figures

Market cap $2.4B · Net margin 10.4% · Return on equity 14.4% · Return on assets (EBIT) 14.9% · Revenue (TTM) 34.4T IDR · Revenue growth (YoY) +10.1% · EPS growth (YoY) −3.5% · Free cash flow 2.5T IDR.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at 78%, PTKFF screens cheaper than that median.

Fair Value models

Bear $0.0669 Fair Value $0.0931 Bull $0.1140

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $0.0445 $0.0636 $0.0901 81

Growth DCF $0.0445 $0.0624 $0.0862 79

Owner Earnings $0.0506 $0.0727 $0.1035 77

All 24 models by family

DCF Models

FCF DCF $0.0445 $0.0636 $0.0901 81

Owner Earnings $0.0506 $0.0727 $0.1035 77

5Y Revenue Exit $0.0595 $0.0966 $0.1450 72

5Y EBITDA Exit $0.0624 $0.1022 $0.1497 74

5Y P/E Exit $0.0734 $0.1232 $0.1771 70

10Y Revenue Exit $0.0511 $0.0817 $0.1249 66

10Y EBITDA Exit $0.0546 $0.0854 $0.1282 68

10Y P/E Exit $0.0610 $0.0989 $0.1478 63

Earnings-Based

Graham-Dodd $0.0395 $0.1399 $0.1883 64

Lynch FV $0.0328 $0.0468 $0.0609 61

PEG = 1.0 $0.0328 $0.0468 $0.0609 57

EPV $0.0511 $0.0572 $0.0622 74

Multiples

P/E Multiple $0.0958 $0.1277 $0.1596 63

P/S Multiple $0.0740 $0.0987 $0.1234 58

P/B Multiple $0.0740 $0.0987 $0.1234 55

EV/EBIT $0.0984 $0.1290 $0.1596 66

EV/EBITDA $0.0822 $0.1074 $0.1326 67

EV/Revenue $0.0721 $0.1002 $0.1283 54

Asset-Based

NCAV (Graham) $0.0185 $0.0247 $0.0369 54

Growth DCF

Growth DCF $0.0445 $0.0624 $0.0862 79

Rev-Margin DCF $0.0595 $0.0960 $0.1392 72

Economic Profit

Residual Income $0.0353 $0.0442 $0.1003 65

ROIC Compounder $0.0540 $0.0652 $0.0781 72

Growth Earnings

Growth-Adj P/E $0.0651 $0.0931 $0.1210 67

Open the full fair value analysis →

Notify me when PTKFF reaches fair value

Put PTKFF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 74/100

Of which business quality 71 · Market factors (momentum, volatility) 29

Profitability 70

Margins and returns on capital today

Quality Growth 56

Are margins and returns improving?

Cashflow 44

Earnings quality: real cash, not paper profit

Fin. Strength 89

Balance sheet, leverage, solvency risk

Investment 85

Disciplined investing over empire-building

Low Volatility 50

Calm price path (market factor)

Momentum 26

Price trend over the last 3–12 months (market factor)

52W Momentum 12

Distance to the 52-week high (market factor)

Net Issuance 92

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 78/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+8.3%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.9%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+8.9%

Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.4%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

+6.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year+6.7%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.7% vs 6%, steady

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 13%

Growth Forecast

Price in line with expectations

The price assumes about as much growth as the company has delivered so far and about what analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+8.2%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+7.4%

Yearly sales growth analysts expect, extended to five years.

Forecast 2026 (sales)+8.0%

Forecast 2027 (sales)+8.5%

Projected 2028 (sales)+7.7%

Projected 2029 (sales)+6.9%

Projected 2030 (sales)+6.1%

Watch PTKFF, get fair value alerts →

Compare PT Kalbe Farma Tbk., with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 72 stocks

Beats the industry median on 8/11 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 74 · Above median

Fair Value upside +72% · Top 25%

Profitability

Return on equity (TTM) 14% · Above median

Return on assets 9% · Above median

Net margin (TTM) 10% · Below median

Operating margin (TTM) 0% · Bottom 25%

Growth and dividend

Revenue growth 10% · Above median

Dividend yield (TTM) 0.0% · Bottom 25%

Balance sheet

Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/FCF 0.0× · Cheapest 25%

PEG 1.11× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Eli Lilly and Company LLY	$1,116	$778.94	−30%
Johnson & Johnson, JNJ	$265.58	$169.04	−36%
AbbVie Inc ABBV	$257.12	$259.66	+1%
Roche Holding RO	CHF 352.60	CHF 306.54	−13%
Merck & Co MRK	€124.22	€101.89	−18%
Novartis AG NVS	$137.16	$138.70	+1%
Novo Nordisk A/S NOVOB	kr 276.45	kr 409.46	+48%
Amgen Inc AMGN	$377.35	$415.09	+10%
Gilead Sciences, Inc GILD	$143.72	$198.51	+38%
Pfizer Inc PFE	$27.72	$20.39	−26%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PT Kalbe Farma Tbk., · Fair Value
$0.0931 +44%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/PTKFF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">PT Kalbe Farma Tbk., · Fair Value</span><br><b style="font-size:20px">$0.0931</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+44%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "PT Kalbe Farma Tbk., Fair Value". https://www.fairvalue-calculator.com/stock/PTKFF

Frequently asked questions

Is PT Kalbe Farma Tbk. (PTKFF) overvalued or undervalued?

As of Sep 13, 2026, our model estimates a fair value of $0.0931 versus a price of $0.0524, about +78% upside (undervalued).

What is the fair value of PTKFF?

Our model-based fair value for PT Kalbe Farma Tbk., is $0.0931 (as of Sep 13, 2026), built from audited fundamentals. The current price: $0.0524.

What is the quality score of PTKFF?

PT Kalbe Farma Tbk., has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for PT Kalbe Farma Tbk. (PTKFF)?

Our model-based price target is the fair value of $0.0931 (as of Sep 13, 2026) from 24 valuation models. Cautious scenario $0.0669, optimistic scenario $0.1140. It is a calculation from audited fundamentals, not an analyst target.

What is the PT Kalbe Farma Tbk., stock forecast for 2026?

Our models put fair value at $0.0931, about +78% upside versus a price of $0.0524 (undervalued). Cautious scenario $0.0669, optimistic scenario $0.1140. The calculation is refreshed regularly with new filings.

What is the revenue of PT Kalbe Farma Tbk. (PTKFF)?

PT Kalbe Farma Tbk., reported trailing-twelve-month revenue of about 34.4T IDR (latest available figure, as of Sep 13, 2026).

What growth is priced into PT Kalbe Farma Tbk. (PTKFF)?

For today's price to be fair in a discounted-cash-flow model, PT Kalbe Farma Tbk., would have to grow free cash flow by +8.2 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.9 % per year. As of Sep 13, 2026.

What discount rate (WACC) does the fair value of PTKFF use?

Our models discount PT Kalbe Farma Tbk., at 11.2 %: a base by market capitalisation (small), country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PT Kalbe Farma Tbk., that is +8.2 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.

How much growth has PT Kalbe Farma Tbk. (PTKFF) delivered so far?

Over the past 5 years revenue at PT Kalbe Farma Tbk., grew +8.9 % a year. The price currently implies +8.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of PT Kalbe Farma Tbk. (PTKFF) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into PT Kalbe Farma Tbk., (+8.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of PT Kalbe Farma Tbk. (PTKFF)?

The free-cash-flow yield on the price is 5.86 %: that much free cash flow PT Kalbe Farma Tbk., produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of PT Kalbe Farma Tbk. (PTKFF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT Kalbe Farma Tbk., it is $0.0931 per share (as of Sep 13, 2026), against a price of $0.0524. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is PT Kalbe Farma Tbk., stock overvalued or undervalued in 2026?

As of Sep 13, 2026, PTKFF trades below its calculated fair value: price $0.0524, fair value $0.0931, a gap of about +78% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of PTKFF?

No. The price is what the market pays today ($0.0524); the fair value is what the company's own numbers justify ($0.0931). For PT Kalbe Farma Tbk., the two are $0.0407 per share apart. That gap is exactly why we show both numbers side by side.

How much is PT Kalbe Farma Tbk., worth?

The market values PT Kalbe Farma Tbk., at about $2.4B (market capitalisation, as of Sep 13, 2026). Per share that is $0.0524; our models calculate a fair value of $0.0931 per share.

What do the bullish and bearish scenarios say about PTKFF?

Our models span a range for PT Kalbe Farma Tbk.,: cautious scenario $0.0669, base $0.0931, optimistic $0.1140 per share (as of Sep 13, 2026, price $0.0524). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of PTKFF?

The PEG ratio of PT Kalbe Farma Tbk., is 1.11 (P/E divided by earnings growth, as of Sep 13, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of PT Kalbe Farma Tbk. (PTKFF)?

Balance-sheet figures for PT Kalbe Farma Tbk., (as of Sep 13, 2026): return on equity 14.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.

How far is PTKFF from its 52-week high?

PT Kalbe Farma Tbk., trades at $0.0524, about 43% below its 52-week high of $0.0912 and 30% above the low of $0.0403 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0931 is for.

Which stocks are comparable to PT Kalbe Farma Tbk.,?

From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is PT Kalbe Farma Tbk., stock attractive at the current price?

The data as of Sep 13, 2026: price $0.0524, calculated fair value $0.0931 (+78%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of PTKFF calculated?

We run PT Kalbe Farma Tbk., through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0931, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 15.8 % above its aggregate fair value. PT Kalbe Farma Tbk., currently trades 78 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What should I pay attention to with PT Kalbe Farma Tbk., right now?

The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($0.0669). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Where does the earnings growth of PT Kalbe Farma Tbk. (PTKFF) come from?

Earnings per share at PT Kalbe Farma Tbk., grew +5.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.0 %, EBIT margin −2.6 %, tax rate +0.2 %, residual (interest, one-offs) +0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of PT Kalbe Farma Tbk.,

How large is the market capitalisation of PT Kalbe Farma Tbk. (PTKFF)?

The market capitalisation of PT Kalbe Farma Tbk., is $2.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the net margin of PT Kalbe Farma Tbk. (PTKFF)?

The net margin of PT Kalbe Farma Tbk., is 10.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of PT Kalbe Farma Tbk. (PTKFF)?

The return on equity (ROE) of PT Kalbe Farma Tbk., is 14.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of PT Kalbe Farma Tbk. (PTKFF)?

On an EBIT basis the return on assets of PT Kalbe Farma Tbk., is 14.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How fast is revenue growing at PT Kalbe Farma Tbk. (PTKFF)?

Revenue at PT Kalbe Farma Tbk., is growing +10.1% versus a year earlier (3y avg +6.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at PT Kalbe Farma Tbk. (PTKFF)?

Earnings per share at PT Kalbe Farma Tbk., are growing −3.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does PT Kalbe Farma Tbk. (PTKFF) hold?

PT Kalbe Farma Tbk., holds more cash than debt, 4.0T IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch PT Kalbe Farma Tbk., in the live analysis

One click puts PT Kalbe Farma Tbk., on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.